Endocyte Inc. (ECYT) Drops 6.4% on February 18

Equities Staff |

Endocyte Inc. (ECYT) was one of the Russell 2000's biggest losers for Thursday February 18 as the stock slid 6.4% to $3.07, a loss of $-0.21 per share. Starting at an opening price of $3.24 a share, the stock traded between $3.00 and $3.35 over the course of the trading day. Volume was 427,739 shares over 813 trades, against an average daily volume of 249,812 shares and a total float of 41.98 million.

The losses send Endocyte Inc. down to a market cap of $128.86 million. In the last year, Endocyte Inc. has traded between $6.76 and $2.65, and its 50-day SMA is currently $3.57 and 200-day SMA is $4.86.

Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.

Endocyte Inc. is based out of West Lafayette, IN and has some 81 employees. Its CEO is P. Ellis.

For a complete fundamental analysis analysis of Endocyte Inc., check out Equities.com’s Stock Valuation Analysis report for ECYT. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…